Accelerating the Clinical Development of Novel Therapeutic Assets
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets designed to transform the standard of care.
Identifying The Opportunity
KEY LEVELS
Key Level #1 - $0.3940
Key Level #2 - $0.4496
Key Level #3 - $0.5199
Support: $0.3002
Medicus Pharma Ltd.
Clinical Pipeline and Technology Platform
- Medicus Pharma is advancing a dual-asset clinical stage portfolio designed to address significant unmet medical needs across dermatology and oncology.
- SkinJect Inc., a wholly owned subsidiary, is developing a patented dissolvable doxorubicin-containing microneedle patch array (D-MNA) for the non-invasive treatment of non-melanoma skin cancer, including basal cell carcinoma.
- Antev Ltd., a subsidiary of Medicus, is developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist for high-risk prostate cancer patients and patients with acute urinary retention due to enlarged prostate.
- The company is also exploring co-development of thermostable infectious disease vaccines combining HelixNano's proprietary mRNA technology with the Medicus microneedle array delivery platform.
Operational Momentum and Scaling
- Medicus Pharma is building a multi-asset precision biotech/life sciences platform across dermatology and oncology while leveraging strategic partnerships across three continents to expand its clinical reach and minimize dilutive capital raises.
- SkinJect®, its lead asset targeting basal cell carcinoma via a patented dissolvable microneedle patch, has received full regulatory and ethical approvals in the United Kingdom and is advancing a Phase 2 clinical trial, with Orphan Drug Designation and registrational IND approval for Gorlin Syndrome patients actively being pursued.
Positioning for Long-Term Growth
- Medicus Pharma is establishing itself as a diversified precision biotech platform across dermatology and oncology, with an expanding global clinical presence across the United States, United Kingdom, and UAE designed to reduce dependence on dilutive financing.
- Pursuit of Orphan Drug Designation and registrational IND approval for Gorlin Syndrome, combined with Phase 2 clinical advancement across multiple geographies, positions Medicus to capture a differentiated share of the growing rare disease and non-melanoma skin cancer market well into the latter half of the decade.
Financials
Medicus Pharma is a clinical-stage company with no product revenues. All financial figures are sourced from SEC filings and company press releases.
Key Financial Highlights:
Cash and cash equivalents: $6.4 million as of March 31, 2026 (compared to $4.0 million as of March 31, 2025)
Net loss for Q1 2026: $9.0 million (compared to $5.1 million in Q1 2025)
Net loss per share Q1 2026: $0.31 (compared to $0.42 in Q1 2025)
R&D expenses Q1 2026: $2.7 million (compared to $2.0 million in Q1 2025)
G&A expenses Q1 2026: $5.9 million (compared to $3.1 million in Q1 2025)
Full year 2024 net loss: $11.2 million
Full year 2025 financing proceeds: approximately $31.9 million raised
Q1 2026 financing: approximately $10 million secured through ATM facility and Standby Equity Purchase Agreement
ATM facility expanded to up to $50 million subsequent to Q1 2026
The company's quarterly report disclosed substantial doubt regarding its ability to continue as a going concern without additional financing. As of March 18, 2025, there were 13,414,801 common shares issued and outstanding.
Introducing the Leadership Team of Medicus Pharma LTD. (Nasdaq: MDCX)
Dr. Raza Bokhari
Executive Chairman and Chief Executive Officer
Dr. Raza Bokhari brings nearly three decades of entrepreneurial and executive leadership in life sciences, healthcare services, and pharmaceutical R&D to Medicus Pharma. A physician-turned-serial-entrepreneur, he has built a distinguished career transforming early-stage and distressed healthcare companies into publicly traded growth enterprises. Prior to Medicus, Dr. Bokhari served as Executive Chairman and CEO of FSD Pharma (Nasdaq: HUGE), where he successfully repositioned the company from medicinal cannabis into clinical-stage pharmaceutical R&D — a strategic pivot punctuated by a Nasdaq listing in January 2020 and the raising of nearly $100 million in institutional capital. Earlier in his career, he generated exceptional returns for investors by recapitalizing and divesting strategic healthcare assets. A recipient of the Philadelphia Business Journal's "40 Under 40" award, Dr. Bokhari also serves as Vice Chairman of the World Affairs Council of Philadelphia. He holds a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University's Fox School of Business and Management.
Carolyn Bonner
President & Chief Financial Officer
Carolyn Bonner brings nearly two decades of leadership experience in the healthcare and life sciences sector to her dual role as President and Chief Financial Officer of Medicus Pharma. Her career spans executive leadership, corporate development, operations, capital markets engagement, and strategic planning across a breadth of healthcare organizations. Prior to Medicus, she served as President and Chief Executive Officer of PCL, Inc., a CAP-accredited specialty laboratory with operations in the United States and the United Arab Emirates. She has also held corporate and business development roles at Rosetta Genomics and Inforte, among other organizations. Having demonstrated strong financial stewardship since stepping into the acting CFO role in September 2025, her formal appointment consolidated operational and financial leadership under a single executive as Medicus advances its clinical pipeline and global development programs.
Dr. Edward Brennan - Chief Scientific Officer
Dr. Edward Brennan contributes more than 25 years of pharmaceutical drug development expertise to Medicus Pharma, with deep experience spanning immunology, oncology, cardiovascular disease, metabolism, and gastroenterology. Over the course of his career, he has held senior medical leadership positions at some of the world's foremost pharmaceutical organizations, including Johnson & Johnson, Pfizer, GlaxoSmithKline, and Wyeth. As Medical Director at both Wyeth and GSK, Dr. Brennan led clinical development programs that resulted in ten FDA drug approvals. His responsibilities across these organizations encompassed all phases of clinical research and direct engagement with regulatory authorities, giving him a comprehensive command of the development pathway from early-stage research through to commercial approval. He brings that regulatory and scientific depth to bear on Medicus Pharma's precision-guided therapeutic pipeline.
We get our information from SEC filings and verified public sources.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
https://www.cuebiopharma.com/https://www.sec.gov/ (CUE SEC Filings)https://www.globenewswire.com/ (Press Releases)https://www.nasdaq.com/ (FY2025 Results)https://www.tradingview.com/symbols/NASDAQ-CUE/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Pursuant to an agreement between JRZ Capital and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $MDCX via digital communications beginning June 2nd, 2026 ending June 5th, 2026. Virtus will be paid $50,000 from JRZ Capital
